Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background:
NTM(Nontuberculous mycobacteria) pulmonary disease is increasing worldwidely, however the diagnosis and treatment of NTM pulmonary disease still has multiple obstacles. The initiation of treatment is not necessary for all patients with NTM pulmonary disease. In addition, the drugs for treatment of NTM pulmonary disease is not enough.
objective. The aim of this prospective registry for Nontuberculous mycobacterial pulmonary disease is to register the NTM pulmonary patients and analysis of the treatment outcome based on the species and to collect the blood and urine samples from the patients for exploring the biomarker for diagnosis and monitoring the NTM pulmonary disease and collect the nontuberculous mycobacterium.
Methods:
Analysis:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NTM pulmonary disease | Cohort Description: adults NTM pulmonary disease patients diagnose by criteria of American thoracic society guideline |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| treatment outcome based on NTM-NET consensus statement |
| At the end of the treatment or 12months after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| biomarker for disease progression: RNA sequence analysis | exploration for various biomarkers with RNA sequence analysis | at the beginning of the treatment |
| biomarker for disease progression: metabolomic analysis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1) not specific
Not provided
Not provided
Not provided
Outpaient clinic and hospitalzed patients in tertiary referral hospital
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Internal Medicine, Yonsei University College of Medicine Division of Pulmonology, Severance Hospital, Yonsei University Health System | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
serum, plasma, urine, RNA and DNA
exploration for various biomarkers with metabolomic analysis
| at the beginning of the treatment |
| biomarker for disease progression: RNA sequence analysis | exploration for various biomarkers with RNA sequence analysis | at the end of the treatment (through study completion, an average of 12 to 15month after treatment) |
| biomarker for disease progression: metabolomic analysis | exploration for various biomarkers with metabolomic analysis | at the end of the treatment (through study completion, an average of 12 to 15month after treatment) |
| biomarker for monitoring of treatment response: RNA sequence analysis | exploration for various biomarkers with RNA sequence analysis | at the beginning of the treatment |
| biomarker for monitoring of treatment response: metabolomic analysis | exploration for various biomarkers with metabolomic analysis | at the beginning of the treatment |
| biomarker for monitoring of treatment response: RNA sequence analysis | exploration for various biomarkers with RNA sequence analysis | at the end of the treatment (through study completion, an average of 12 to 15month after treatment) |
| biomarker for monitoring of treatment response: metabolomic analysis | exploration for various biomarkers with metabolomic analysis | at the end of the treatment (through study completion, an average of 12 to 15month after treatment) |